Stocks · News reference

JP Morgan Maintains Neutral on Upstream Bio, Raises Price Target to $9

Aug 14, 2026, 4:14 PMBenzinga Newsdesk

JP Morgan analyst Tessa Romero maintains Upstream Bio (NASDAQ:UPB) with a Neutral and raises the price target from $8 to $9.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

Globenewswire IncSep 8, 2026, 7:30 AMNot Specified
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
Upstream Bio announced positive Phase 2 VALIANT trial results for verekitug, a TSLP receptor antagonist, showing a 56% reduction in annualized asthma exacerbation rate at 100 mg every 12 weeks versus placebo. The company plans to initiate Phase 3 trials in Q1 2027 evaluating a 400 mg quarterly dosing regimen in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP).
UPB
BenzingaSep 8, 2026, 7:55 AMBenzinga Newsdesk
Upstream Bio Presented Results From The Phase 2 VALIANT Clinical Trial Evaluating The Safety And Efficacy Of Verekitug In Adults With Severe Asthma In A Late-breaking Oral Presentation At The European Respiratory Society Congress 2026 In Barcelona
UPB
BenzingaSep 2, 2026, 11:25 AMBenzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Upstream Bio, Maintains $36 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Upstream Bio (NASDAQ:UPB) with a Buy and maintains $36 price target.
UPB
BenzingaSep 1, 2026, 11:06 AMBenzinga Newsdesk
Upstream Bio Announces Phase 3 Plans For Verekitug At 400 mg Every 12 Weeks In Severe Asthma And CRSwNP, With About 1,500 Patients Across Two Placebo-Controlled Trials; On Track To Initiate Q1 2027
UPB